Skip to main content

Rivian Rides High as California and Washington D.C. Clash Over EV Tax Credits

California Governor Gavin Newsom has reignited the electric vehicle (EV) tax credit debate.

Cybertruck Tesla and R1T Rivian, best stocks to buy, learn a trade

The governor proposes a state-level rebate program in anticipation of President-elect Donald Trump's expected repeal of federal EV tax credits. Newsom’s plan, aimed at fostering competition in the zero-emission vehicle market, has sparked speculation that Tesla (TSLA) may be excluded from the new rebates, a move that could reshape the EV landscape.

Tesla, which accounts for about half of all U.S. EV sales, saw its stock drop 4% on Monday following the announcement. In contrast, shares of Rivian Automotive (RIVN) surged over 13%, buoyed by the potential boost to competition. Analysts believe a cap on Tesla’s eligibility for state rebates could level the playing field for smaller competitors like Rivian.

Rivian Secures DOE Loan, Eyes Massive Growth
In a separate development, Rivian announced it has received conditional approval for a $6.6 billion loan from the Department of Energy's Advanced Technology Vehicle Manufacturing program. The funds will support the construction of a new facility in Georgia capable of producing 400,000 vehicles annually.

Rivian CEO RJ Scaringe emphasized the significance of the loan, stating, "This will enable us to aggressively scale our U.S. manufacturing footprint for competitively priced R2 and R3 vehicles." The factory, set to begin production in 2028, is expected to create thousands of jobs and strengthen Rivian’s position in both domestic and international markets.

Despite the ambitious plans, Rivian still faces hurdles, including satisfying legal and environmental conditions for the loan. Moreover, the company has struggled to scale up production, with fewer than 50,000 vehicles expected this year. However, Rivian’s cash reserves of $7.85 billion provide a cushion as it gears up for expansion.

Tesla’s Uncertain Path Amid Policy Shifts
Tesla, long considered the leader in the EV market, faces an uncertain path as political dynamics shift. While the company’s scale and cost structure allow it to thrive without federal incentives, losing access to state-level credits in California—its largest U.S. market—could impact its market share.

The potential repeal of federal tax credits also threatens Tesla’s lucrative zero-emission vehicle (ZEV) credit sales, which have generated nearly $10 billion since 2018. Analysts warn that federal opposition to California’s rebate program could further complicate Tesla’s operations.

Despite the headwinds, Tesla has maintained investor confidence, with its stock up 40% since the November election. Analysts, such as Wedbush’s Dan Ives, remain bullish, citing Tesla's leadership in the EV space and its ability to navigate regulatory challenges.

Conclusion: The Road Ahead
As the battle over EV tax credits unfolds, Rivian and Tesla find themselves at pivotal crossroads. Rivian’s ambitious plans and government backing position it as a rising challenger, while Tesla’s dominance could be tested by shifting policies and increasing competition. Investors should brace for continued volatility as the EV market adjusts to these political and financial shifts.


Considering a $1,000 investment in these companies? 

Our team at Stock Investor carefully curated a list of top stocks with the potential for significant returns, suitable for beginners and seasoned investors alike who are eager to learn a trade and unearth the best stocks to buy. Though not featured in this article, these selected stocks could be game-changers in the future.

For those seeking dynamic trading experiences, consider joining our Swing Trade AlertsOption Income Alert, or our Trading RoomTake advantage of our special offer today, starting at just $1 in the first month.

Unlock the secrets of Smart Money

Explore how billionaires and institutions are influencing the market. Follow their every move with DarkOption Flow and stay updated on essential market insights. Begin your journey to informed investing today!

Education

And if you're a fan of Invest opedia, you'll appreciate what we offer at SharperTrades even more. Explore our comprehensive option trading course and technical trading course, where you can learn trading, analyze stocks, delve into chart patterns for stocks, and gain invaluable insights for making the best company investments.

Unlock Your Stock Market Edge with SharperTrades. Dive into powerful trading tools, learn a trade, and receive expert guidance. Stay up-to-date with regular market updates. Learn trading, basics of investing, and how to pick the best stocks to buy. Whether you're a beginner or seasoned investor and trader, we've got you covered. Get started for free, today!



Trading Risk Disclaimer

​All the information shared is provided for educational purposes only. Any trades placed upon the reliance of SharperTrades, LLC, and/or DarkOption Flow are taken at your own risk for your own account. Past performance is no guarantee. While there is great potential for reward in trading stocks, cryptos, commodities, options, forex, and other trading securities, there is also a substantial risk of loss. All trading operations involve a high risk of losing your entire investment. You must therefore decide your own suitability to trade. Trading results can never be guaranteed. SharperTrades, LLC and DarkOption Flow are not registered as investment advisers with any federal or state regulatory agency. This is not an offer to buy or sell stocks, cryptos, forex, futures, options, commodity interests, or any other trading securities. SharperTrades, LLC and DarkOption Flow are not brokers and do not accept deposits. Purchases should not be considered deposits. The technical solution offered by the DarkOption Flow platforms is provided by a third party.

Popular posts from this blog

Nvidia’s AI Leadership Faces Challenges Amid Evolving Semiconductor Landscape

Super Micro Computer’s Volatile Comeback: A Long Road to Stability

Hims & Hers Health Surges Amid FDA Nomination, GLP-1 Opportunity